Participated in establishing clinical trials of fetal neural
transplantation therapy for Parkinson disease (University of
South Florida College of Medicine, 1993-1995), provided the
scientific evidence for proceeding with the first world
transplant therapy (using neuroteratocarinoma cells) in stroke
patients (Layton Bioscience Inc, 1998), and the development of
spheramine retinal pigmented epithelial cell transplants in
Parkinson disease (Titan Pharmaceuticals, reached Phase IIb
clinical trials, 2007).
Research Interests
By advocating a lab-to-clinic translational research theme,
my laboratory works closely with NIH and FDA in evaluating the
potential of cell therapy in adult stroke and neonatal
hypoxic-ischemic injury (cerebral palsy). We are desirous in
identifying transplantable adult stem cells (e.g., bone marrow,
amnion/ placenta cells, and umbilical cord) that are safe and
effective for clinical application. The overarching goal is to
exploit stem cells as therapeutic agents for neurorestoration of
the diseased or aging brain.